No Data
No Data
No Data
No Data
No Data
Press Release: SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the "Company" or "SAB"), a clinical-stage biopharmac
Dow JonesMay 6 19:15
SAB Biotherapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
SAB Biotherapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow JonesApr 17 01:38
HC Wainwright & Co. : The SAB Biotherapeutics (SABS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $6.00.
HC Wainwright & Co. : The SAB Biotherapeutics (SABS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $6.00.
Zhitong FinanceApr 17 01:31
Analysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Compass Therapeutics (CMPX)
TipRanksApr 16 22:00
Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $25 Price Target
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics with a Buy and maintains $25 price target.
Analyst UpgradesApr 16 19:41
SAB Biotherapeutics' Has Completed Dosing The Third Cohort For Phase 1 Study Of SAB-142 In Healthy Volunteers And Participants With Type 1 Diabetes With No Observation Of Serum Sickness Thus Far
SAB Biotherapeutics' Has Completed Dosing The Third Cohort For Phase 1 Study Of SAB-142 In Healthy Volunteers And Participants With Type 1 Diabetes With No Observation Of Serum Sickness Thus Far
BenzingaApr 16 19:17
No Data
No Data